Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. EDTAKI: a Nephrology and Public Policy Committee platform call for more European involvement in acute kidney injury

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab

    Research output: Contribution to journalLetterResearchpeer-review

  1. Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Microbiome and metabolome features of the cardiometabolic disease spectrum

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Niels S Heinrich
  • Simone Theilade
  • Signe A Winther
  • Nete Tofte
  • Tarunveer S Ahluwalia
  • Jørgen L Jeppesen
  • Frederik Persson
  • Tine W Hansen
  • Jens P Goetze
  • Peter Rossing
View graph of relations

BACKGROUND: Plasma copeptin is a surrogate of arginine vasopressin (AVP) secretion and is associated with a risk of renal and cardiovascular disease. We investigated associations between copeptin and renal events, cardiovascular events and mortality in type 1 diabetes (T1D).

METHODS: We conducted a prospective cohort study on 658 individuals with T1D from Steno Diabetes Center Copenhagen. Plasma copeptin concentrations and conventional risk factors were assessed at baseline. The five endpoints were traced through national registries and electronic laboratory records.

RESULTS: Baseline mean age was 55 ± 13 years and estimated glomerular filtration rate (eGFR) was 81 ± 26 mL/min/1.73 m2. The median follow-up was 6.2 years (interquartile range 5.8-6.7); 123 participants reached a combined renal endpoint [decline in eGFR ≥30%, end-stage kidney disease (ESKD) or all-cause mortality], 93 had a decrease in eGFR ≥30%, 21 developed ESKD, 94 experienced a combined cardiovascular endpoint and 58 died from all causes. Higher copeptin was associated with all endpoints in unadjusted Cox regression analyses. Upon adjustment for baseline eGFR, the associations were attenuated and remained significant only for the combined renal endpoint and decrease in eGFR ≥30%. Results were similar upon further adjustment for other risk factors, after which hazard ratios for the two renal endpoints were 2.27 (95% confidence interval 1.08-4.74) and 4.49 (1.77-11.4), respectively, for the highest versus the lowest quartile of copeptin.

CONCLUSIONS: Higher copeptin was an independent risk marker for a combined renal endpoint and decline in renal function. AVP may be a marker of renal damage or a factor whose contribution to renal and cardiovascular risk is partially mediated by renal damage.

Original languageEnglish
Article numbergfaa308
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Volume37
Issue number1
Pages (from-to)100-107
Number of pages8
ISSN0931-0509
DOIs
Publication statusPublished - Jan 2022

    Research areas

  • cardiovascular, copeptin, mortality, renal function, type 1 diabetes

ID: 61598785